Year: 2026

Fourth Quarter Revenue Increased 20% to a Record $23.4 Million Full Year 2025 Revenue Increased 20% to $90.3 Million, Generating GAAP EPS of $0.91 BOCA RATON, Fla., March 04, 2026 (GLOBE NEWSWIRE) — Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced financial results for the fourth quarter and full year ended December 31, 2025. “We concluded 2025 with record fourth quarter results, capping a year defined by disciplined execution and continued momentum across the enterprise,” stated Derek Dubner, red violet’s CEO. “Our cloud-native architecture, embedded artificial intelligence, and extensive longitudinal identity graph continue to differentiate us in the marketplace, particularly in regulated and mission-critical environments. The durability and scalability of our model are...

MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the fourth quarter and full year ended December 31, 2025 and initiated financial guidance for full year 2026.   Recent Financial HighlightsGenerated fourth quarter 2025 total revenue of $20.4 million, an increase of 7% compared to the same period in the prior year, and full year 2025 total revenue of $77.4 million, a decrease of 3% compared to full year 2024. Achieved total gross margin of 87% in the fourth quarter of 2025 compared to 87% in the same period in the prior year,...

PORTLAND, Maine, March 04, 2026 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced its unaudited financial results for the year ended December 31, 2025. Management’s Discussion: “Today we are reporting 2025 net operating income of $1.6 million, an increase of $3.3 million compared to 2024. These results were largely driven by a significant improvement in gross margin, reflecting higher volumes, manufacturing efficiencies, and price realization,” commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. “Net loss for 2025 was $1.0 million, an improvement of $1.1 million compared to 2024. As previously discussed, we saw several non-recurring items in 2025...

– Results Improved in All Segments – – Q4 2025 Gross Profit of $15.2 Million Increased $16.6 Million, Q4 2025 Net Income of $21.5 Million, or $0.28 per Share, Improved $63.5 Million, and Q4 2025 Adjusted EBITDA of $27.9 Million Grew $35.6 Million Compared to Q4 2024 – PEKIN, Ill., March 04, 2026 (GLOBE NEWSWIRE) — Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, reported its financial results for the quarter and year ended December 31, 2025. President and Chief Executive Officer Bryon McGregor commented, “The fourth quarter capped a year of strong execution and marked a pivotal milestone in our strategic realignment. Over the course of 2025, we completed the heavy lifting of addressing losses at underperforming assets,...

MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) — BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the fourth quarter and full year ended December 31, 2025 and raised guidance for full year 2026. Financial Highlights:Total revenue of $96.1 million in the fourth quarter of 2025, compared to $45.1 million in the fourth quarter of 2024, an increase of 113%. Prenatal clinical testing revenue was $86.1 million in the fourth quarter of 2025, an increase of 99% from the fourth quarter 2024. Oncology clinical testing revenue was $9.1 million in the fourth quarter of 2025, more than 8x higher than the $1.1 million reported in the fourth quarter of 2024. Gross profit margin was...

28% growth in fourth quarter revenue to $44.4 million Annual refrigerant sales volume grew by 6% Annual refrigerant reclamation volume increased by 18% for second consecutive year Maintained strong, unlevered balance sheet Completed accretive acquisition of Refrigerants Inc. Board approved $20 million share repurchase authorization for 2026WOODCLIFF LAKE, N.J., March 04, 2026 (GLOBE NEWSWIRE) — Hudson Technologies, Inc. (NASDAQ: HDSN) announced results for the fourth quarter and year ended December 31, 2025. Kenneth Gaglione, President and Chief Executive Officer of Hudson Technologies commented, “Hudson delivered a strong finish to 2025 with fourth quarter results that included revenue growth of 28% and the successful execution of our accretive acquisition of Refrigerants Inc. “We also achieved a second consecutive year of...

Fourth Quarter ResultsTotal revenues of $50.6 million, a 13% year-over-year improvement and exceeding the high end of prior guidance Operating income of $5.2 million increased 78% year-over-year, outpacing revenue growth Net income of $15.0 million ($5.34 per diluted share), including a net positive impact of $9.8 million related to the release of our deferred tax valuation allowance Adjusted EBITDA of $9.2 million, compared to $8.2 million in the fourth quarter of 2024 and exceeding the high end of prior guidance $36.7 million in cash and $7.6 million in debt as of December 31, 2025Full Year ResultsTotal revenues of $183.6 million, a 13% improvement over 2024 Operating income more than doubled to $10.5 million from $4.3 million in 2024 Net income of $23.7 million ($8.65 per diluted share), including a net positive impact of $11.5...

LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2025. “The previous year was an important period of transition for the Company, during which we sharpened our strategic priorities,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. “With that foundation in place, our attention is firmly on execution – advancing rinvatercept into a Phase 2 clinical trial in patients...

RESTON, Va., March 04, 2026 (GLOBE NEWSWIRE) — Bowman Consulting Group Ltd. (NASDAQ: BWMN), a national engineering services and program management firm, today announced record financial results for the fourth quarter and full year ended December 31, 2025. The company also raised net service billing guidance for 2026. “We delivered a record year in 2025,” said Gary Bowman, founder and CEO of Bowman. “Our focus on execution, organic growth and strategic acquisition is evident in our results. With double-digit growth of organic net service revenue, more than 100 basis point increase in adjusted EBITDA margin, improved cash conversion and the completion of several consequential acquisitions, we entered 2026 with strong momentum in the business and confidence in our markets. We’re well positioned for another breakout year as we...

Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 days On track to submit regulatory applications for Anaphylm in Canada and the EU in 2026 Extends revenue sharing agreement with RTW to June 30, 2027 Excluding one-time items, meets 2025 guidance for revenue and non-GAAP adjusted EBITDA loss Guides to end FY2026 with cash and cash equivalents of $70 million Company to host investment community conference call on March 5, 2026WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today reported financial results...